Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies to neutralize these variants. We compared antibody binding and live virus neutralization of sera from naturally infected and spike mRNA vaccinated individuals against a circulating SARS-CoV-2 B.1 variant and the emerging B.1.351 variant. In acutely-infected (5-19 days post-symptom onset), convalescent COVID-19 individuals (through 8 months post-symptom onset) and mRNA-1273 vaccinated individuals (day 14 post-second dose), we observed an average 4.3-fold reduction in antibody titers to the B.1.351-derived receptor binding domain of the spike protein and an average 3.5-fold reduction in neutralizing antibody titers to the SARS-CoV-2 B.1.351 variant as compared to the B.1 variant (spike D614G). However, most acute and convalescent sera from infected and all vaccinated individuals neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective immunity is retained against COVID-19.

[1]  K. Subbarao,et al.  Persistence of SARS-CoV-2–Specific IgG in Children 6 Months After Infection, Australia , 2021, Emerging infectious diseases.

[2]  N. Sullivan,et al.  Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report. , 2021, The New England journal of medicine.

[3]  S. Kishigami,et al.  SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity , 2021, Nature Communications.

[4]  Vineet D. Menachery,et al.  Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant , 2021, medRxiv.

[5]  B. Haynes,et al.  SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines , 2021, bioRxiv.

[6]  Vineet D. Menachery,et al.  Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera , 2021, bioRxiv.

[7]  D. Fremont,et al.  Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization , 2021, Cell Host & Microbe.

[8]  Vineet D. Menachery,et al.  Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis , 2021, Nature.

[9]  Larissa B. Thackray,et al.  Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein , 2021, Cell.

[10]  A. García-Sastre,et al.  The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera , 2021, medRxiv.

[11]  L. Morris,et al.  SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, bioRxiv.

[12]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[13]  James D. Allen,et al.  Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection , 2020, bioRxiv.

[14]  B. Haynes,et al.  D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction , 2020, Cell Reports.

[15]  Sergei L. Kosakovsky Pond,et al.  Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa , 2020, medRxiv.

[16]  J. Mascola,et al.  Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.

[17]  Vineet D. Menachery,et al.  Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS‐CoV‐2 Neutralizing Antibodies , 2020, Current protocols in immunology.

[18]  R. Paredes,et al.  Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes , 2020, bioRxiv.

[19]  M. Nussenzweig,et al.  Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo , 2020, The Journal of experimental medicine.

[20]  Sarah K. Hilton,et al.  Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition , 2020, Cell Host & Microbe.

[21]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to eight months after infection , 2020, bioRxiv.

[22]  R. Bruno,et al.  Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection , 2020, bioRxiv.

[23]  R. Baric,et al.  Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.

[24]  M. Beltramello,et al.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.

[25]  Sarah K. Hilton,et al.  Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition , 2020, bioRxiv.

[26]  J. Waggoner,et al.  Metagenomic sequencing to detect respiratory viruses in persons under investigation for COVID-19 , 2020, medRxiv.

[27]  Vineet D. Menachery,et al.  Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility , 2020, Nature.

[28]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[29]  Vineet D. Menachery,et al.  Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients , 2020, Cell Reports Medicine.

[30]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[31]  D. Cummings,et al.  Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus , 2018, PLoS neglected tropical diseases.

[32]  D. Sommers,et al.  A longitudinal analysis , 1992 .